The Cure Alzheimer’s Fund 2023 Annual Report is Now Available
2023 marked our 19th consecutive year of record-breaking results for contributions raised to fund research into Alzheimer’s disease totaling $34.9 million and distribution of research grants totaling $27.8 million. This year, our report is available in its entirety as well as in segments. To access each segment, click on the title and you will link to the page on CureAlz.org.
—
- Letter from the Chair of Cure Alzheimer’s Fund, Henry McCance
- Letter from our Chief Executive Officer, Meg Smith
- Letter from the Chair of our Research Leadership Group, Dr. Rudy Tanzi
- Financial Summary of our Source and Use of Funds
- Form 990
- Audited Financial Statements
- An Overview of our Research Results
- An Overview of our Research Areas of Focus
- A List of the Funded Research Projects in 2023
- A List of all of the Papers Published in 2023 as a result of CureAlz Grants
The FDA Approves KisunlaTM for Early Symptomatic Alzheimer’s Disease
On July 2, the FDA approved donanemab for the treatment of early symptomatic Alzheimer’s disease. Eli Lilly’s new once monthly IV infusion will be sold under the brand name KisunlaTM. Additional information about KisunlaTM and its approval is available on the CureAlz website.
We Are Proud of Our Diversified Research Funding Portfolio!
Since our founding, we have believed that it is essential – critical! – to provide funding to a broad range of scientific theory and discovery, and as detailed in our annual report, this continues to be a cornerstone of our non-profit. The newly approved anti-amyloid drugs encourage us to continue to support research aimed at better targeting this pathology, along with other aspects of Alzheimer’s disease. In 2023, we provided grants to investigations of tau, inflammation and the role of immune cells, genetics, the microbiome, lifestyle including exercise, diet, sleep, and stress, and many other areas.
We are the funder that our exceptional and passionate researchers turn to for support of the unconventional ideas that will become new extraordinary contributions to the understanding of the disease; we and they are deeply grateful to the generosity of our donors that makes these leaps forward possible. We are excited to see what our researchers discover in the broad range of projects we are funding in 2024 and for the future therapies enabled by these discoveries.
Thank You for Your Generosity
Today, 6.9 million people in the United States are living with a diagnosis of Alzheimer’s disease. Your gifts have enabled Cure Alzheimer’s Fund to support researchers who are relentless in their desire to understand Alzheimer’s disease. New information is emerging every day and there is great momentum in the field, but so much more to learn and discover.
100% of all general donations go to support our research and your gift will contribute to this progress so that we may realize a world without Alzheimer’s disease. If you recently made a donation to Cure Alzheimer’s Fund, thank you. If not, please consider making a gift today.
Thank you.
—The Cure Alzheimer’s Fund Team